Please use this identifier to cite or link to this item:
Title: Montelukast ameliorates streptozotocin-induced cognitive impairment and neurotoxicity in mice
Authors: Zhang, CT
Lin, JR
Wu, F
Ghosh, A
Tang, SS
Hu, M
Long, Y
Sun, HB
Hong, H
Keywords: Montelukast
Cysteinyl leukotriene receptor 1
Issue Date: 2016
Publisher: Elsevier
Source: Neurotoxicology, Dec. 2016, v. 57, p. 214-222 How to cite?
Journal: Neurotoxicology 
Abstract: Extensive studies have demonstrated that neuroinflammation is associated with Alzheimer's disease (AD) and cysteinyl leukotriene receptor 1 (CysLT(1)R) was involved in neuroinflammation. Montelukast, a highly selective CysLT1R antagonist, has been reported to attenuate learning and memory impairments in the amyloid-beta-induced mouse model of AD. However, whether montelukast also exerts beneficial effects on streptozotocin (STZ)-induced memory deficits in mice is not well known. In the present study, we aimed to investigate the effects of montelukast on STZ-induced cognitive impairment, neuroinflammation and apoptosis in mice. Our data showed that intra-hippocampal microinfusion of STZ resulted in learning and memory impairments, including increased escape latency during acquisition trials and decreased exploratory activities in the probe trial in Morris watermaze (MWM) task, and decreased number of correct choices and increased latency to enter the shock-free compartment in Y-maze test, and caused neuroinflammatory and apoptotic responses, evidenced by increments of nuclear NF-kappa B p65, TNF-alpha, IL-1 beta, cleaved caspase-3, Bax as well as decreased expression of Bcl-2 in hippocampus. Interestingly, STZ treatment led to up-regulation of protein and mRNA of CysLT(1)R in hippocampus. Of note, consecutive oral administration of montelukast (1 or 2 mg/kg, 3 weeks) remarkably attenuated these effects induced by STZ. However, montelukast had no effect on normal mice. These results suggest that montelukast improves memory impairment and inhibits neuroinflammation and apoptosis in mice exposed to STZ. Montelukast may provide a novel strategy for treating or preventing AD.
ISSN: 0161-813X
EISSN: 1872-9711
DOI: 10.1016/j.neuro.2016.09.022
Appears in Collections:Journal/Magazine Article

View full-text via PolyU eLinks SFX Query
Show full item record

Page view(s)

Last Week
Last month
Checked on Aug 20, 2017

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.